Calidi Biotherapeutics raises $3M from Dr. Ronald Rigor; launches Nova Cell subsidiary with $2M investment

Calidi Biotherapeutics, Inc.

Dr. Ronald Rigor invests $1M in Calidi via 698,812 shares at $1.431 and warrants for 600,000 shares at $1.90.
Dr. Rigor invests $2M in Nova Cell subsidiary for 25% fully-diluted equity; IP assigned to Nova Cell.
Dr. Rigor appointed to Scientific and Medical Advisory Board; receives 5,000 stock options.
Exclusive license for Philippines for AAA stem cells and CLD-201; initial revenue expected 2025.
Nova Cell to focus on regenerative medicine, cosmetics, orthopedics; Calidi retains oncology focus.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.